Why Gilead Sciences leans on Veklury in the antiviral toolbox

Reviewed: ad hoc news Classics & Longseller desk. Edited and checked on 2026-06-20, 10:11. Details in the imprint.

With Veklury, Gilead Sciences has a drug that many hospital physicians now order almost routinely when a vulnerable Covid-19 patient arrives short of breath and anxious. The clear infusion bag, cold in the hand, stands for a therapy that moved from emergency spotlight to quiet standard.

What Veklury is meant to do

Veklury is an intravenously administered antiviral designed to block replication of SARS-CoV-2 by targeting the viral RNA polymerase. In practice that means a nurse hanging a short infusion while monitors beep and oxygen flows, aiming to stop the virus before lungs deteriorate further.

Regulators framed its role narrowly: hospitalized adults and certain children with Covid-19 who need supplemental oxygen but are not yet in full organ failure. So Veklury lives in a specific window of disease, after mild infection and before intensive care, where days gained can translate into fewer complications.

How the treatment course looks on the ward

On the ward, Veklury usually starts with a loading dose on day one, followed by smaller daily doses for several days. For the patient this means one short drip per day, often less dramatic than the word “antiviral” suggests, but still a fixed daily ritual.

Doctors describe a practical pattern: identify high-risk patients early, check kidney and liver parameters, then start the infusion while continuing oxygen and standard care. When it works as intended, progression slows, oxygen demand stabilizes, and the patient can sit up in bed earlier than feared.

Benefits that keep it relevant

Even after the acute pandemic, Veklury still offers a few convincing advantages that keep it on hospital shelves. It is a known quantity with a defined safety profile, lab logistics are established, and physicians know which patients are most likely to benefit.

In health systems that still face waves of infections among older or immunocompromised people, this familiarity matters. Hospital teams do not want to relearn workflows every season; they want a therapy that fits into existing emergency protocols and electronic order sets.

Where the limits show up

The flip side is that Veklury is not a universal Covid solution. It requires intravenous access and monitoring, so it is not a quick pill for mild cases at home but a hospital-only option bound to beds, infusion pumps, and staff time.

Timing also hurts its potential. If patients present late with advanced organ failure, the benefit shrinks sharply. Conversely, those with very mild symptoms often do not meet criteria or do not want a multi-day infusion, so another treatment or simple observation is chosen.

Pricing, access, and daily reality

Pricing has been controversial from the beginning, but on the floor the discussion feels more pragmatic. For physicians, the key question is whether the drug can prevent intensive-care stays or shorten hospitalizations, which can more than offset the cost of a few vials.

For patients, what counts is different: they notice the cold of the infusion line, the brief wait until the bag runs dry, and the relief when doctors say that markers and breathing are moving in the right direction. Veklury becomes one element in a bundle of interventions that, together, keep them off a ventilator.

Why Veklury still matters for Gilead

For Gilead Sciences, Veklury has turned from a sudden pandemic spike into a classic, steadily aging product that still throws off meaningful revenue. It fills a strategic gap between HIV antivirals, hepatitis therapies, and newer oncology ambitions.

Shares of Gilead Sciences (US3755581036) trade in the US on Nasdaq; the company’s performance remains linked not only to Veklury but also to its broader antiviral and oncology portfolio.

This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.